Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS

Background/aims: Polycystic ovary syndrome (PCOS) is associated with insulin resistance, adrenal hyperactivity and decreased mental health. We aimed to investigate the changes in adrenal activity, metabolic status and mental health in PCOS during treatment with escitalopram or placebo. Methods: For...

Full description

Bibliographic Details
Main Authors: Dorte Glintborg, Magda Lambaa Altinok, Pernille Ravn, Kurt Bjerregaard Stage, Kurt Højlund, Marianne Andersen
Format: Article
Language:English
Published: Bioscientifica 2018-03-01
Series:Endocrine Connections
Subjects:
Online Access:http://www.endocrineconnections.com/content/7/3/490.full
id doaj-7cc329b6d82943c79571d3af65b735d4
record_format Article
spelling doaj-7cc329b6d82943c79571d3af65b735d42020-11-25T00:15:59ZengBioscientificaEndocrine Connections2049-36142049-36142018-03-017311110.1530/EC-18-0077Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOSDorte Glintborg0Magda Lambaa Altinok1Pernille Ravn2Kurt Bjerregaard Stage3Kurt Højlund4Marianne Andersen5Department of Endocrinology and Metabolism, Odense University Hospital, Odense, DenmarkDepartment of Endocrinology and Metabolism, Odense University Hospital, Odense, DenmarkDepartment of Gynecology and Obstetrics, Odense University Hospital, Odense, DenmarkDepartment of Psychiatry, Odense University Hospital, Odense, DenmarkDepartment of Endocrinology and Metabolism, Odense University Hospital, Odense, DenmarkDepartment of Endocrinology and Metabolism, Odense University Hospital, Odense, DenmarkBackground/aims: Polycystic ovary syndrome (PCOS) is associated with insulin resistance, adrenal hyperactivity and decreased mental health. We aimed to investigate the changes in adrenal activity, metabolic status and mental health in PCOS during treatment with escitalopram or placebo. Methods: Forty-two overweight premenopausal women with PCOS and no clinical depression were randomized to 12-week SSRI (20 mg escitalopram/day, n = 21) or placebo (n = 21). Patients underwent clinical examination, fasting blood samples, adrenocorticotroph hormone (ACTH) test, 3-h oral glucose tolerance test (OGTT) and filled in questionnaires regarding mental health and health-related quality of life (HRQoL): WHO Well-Being Index (WHO-5), Major Depression Inventory (MDI), Short Form 36 (SF-36) and PCOS questionnaire. Results: Included women were aged 31 (6) years (mean (s.d.)) and had body mass index (BMI) 35.8 (6.5) kg/m2 and waist 102 (12) cm. Escitalopram was associated with increased waist (median (quartiles) change 1 (0; 3) cm), P = 0.005 vs change during placebo and increased cortisol levels (cortisol 0, cortisol 60, peak cortisol and area under the curve for cortisol during ACTH test), all P < 0.05 vs changes during placebo. Escitalopram had no significant effect on measures of insulin sensitivity, insulin secretion, fasting lipids, mental health or HRQoL. Conclusion: Waist circumference and cortisol levels increased during treatment with escitalopram in women with PCOS and no clinical depression, whereas metabolic risk markers, mental health and HRQol were unchanged.http://www.endocrineconnections.com/content/7/3/490.fullPCOScortisolmental healthquality of lifePCOSQescitalopramSSRI
collection DOAJ
language English
format Article
sources DOAJ
author Dorte Glintborg
Magda Lambaa Altinok
Pernille Ravn
Kurt Bjerregaard Stage
Kurt Højlund
Marianne Andersen
spellingShingle Dorte Glintborg
Magda Lambaa Altinok
Pernille Ravn
Kurt Bjerregaard Stage
Kurt Højlund
Marianne Andersen
Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS
Endocrine Connections
PCOS
cortisol
mental health
quality of life
PCOSQ
escitalopram
SSRI
author_facet Dorte Glintborg
Magda Lambaa Altinok
Pernille Ravn
Kurt Bjerregaard Stage
Kurt Højlund
Marianne Andersen
author_sort Dorte Glintborg
title Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS
title_short Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS
title_full Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS
title_fullStr Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS
title_full_unstemmed Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS
title_sort adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in pcos
publisher Bioscientifica
series Endocrine Connections
issn 2049-3614
2049-3614
publishDate 2018-03-01
description Background/aims: Polycystic ovary syndrome (PCOS) is associated with insulin resistance, adrenal hyperactivity and decreased mental health. We aimed to investigate the changes in adrenal activity, metabolic status and mental health in PCOS during treatment with escitalopram or placebo. Methods: Forty-two overweight premenopausal women with PCOS and no clinical depression were randomized to 12-week SSRI (20 mg escitalopram/day, n = 21) or placebo (n = 21). Patients underwent clinical examination, fasting blood samples, adrenocorticotroph hormone (ACTH) test, 3-h oral glucose tolerance test (OGTT) and filled in questionnaires regarding mental health and health-related quality of life (HRQoL): WHO Well-Being Index (WHO-5), Major Depression Inventory (MDI), Short Form 36 (SF-36) and PCOS questionnaire. Results: Included women were aged 31 (6) years (mean (s.d.)) and had body mass index (BMI) 35.8 (6.5) kg/m2 and waist 102 (12) cm. Escitalopram was associated with increased waist (median (quartiles) change 1 (0; 3) cm), P = 0.005 vs change during placebo and increased cortisol levels (cortisol 0, cortisol 60, peak cortisol and area under the curve for cortisol during ACTH test), all P < 0.05 vs changes during placebo. Escitalopram had no significant effect on measures of insulin sensitivity, insulin secretion, fasting lipids, mental health or HRQoL. Conclusion: Waist circumference and cortisol levels increased during treatment with escitalopram in women with PCOS and no clinical depression, whereas metabolic risk markers, mental health and HRQol were unchanged.
topic PCOS
cortisol
mental health
quality of life
PCOSQ
escitalopram
SSRI
url http://www.endocrineconnections.com/content/7/3/490.full
work_keys_str_mv AT dorteglintborg adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos
AT magdalambaaaltinok adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos
AT pernilleravn adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos
AT kurtbjerregaardstage adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos
AT kurthøjlund adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos
AT marianneandersen adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos
_version_ 1725385509629329408